340962-88-1

Usage

Uses

Used in Research Applications:
1-(1-Benzylpiperidin-4-yl)pyrrolidin-2-one is utilized as a research chemical for studying the effects of stimulants on the central nervous system. It aids in understanding the mechanisms of action and potential risks associated with substances that produce similar effects to traditional stimulants.
Used in Pharmaceutical Development:
Although not approved for medical use, NPP may be employed in the development of pharmaceuticals targeting specific conditions that could potentially benefit from stimulant-like effects, under strict regulatory oversight and within the confines of the law.
Used in Forensic Toxicology:
1-(1-Benzylpiperidin-4-yl)pyrrolidin-2-one is used in forensic toxicology as a reference substance to identify and analyze designer drugs in cases of drug abuse or poisoning.

InChI:InChI=1/C16H22N2O/c19-16-7-4-10-18(16)15-8-11-17(12-9-15)13-14-5-2-1-3-6-14/h1-3,5-6,15H,4,7-13H2

Upstream product

• 616-45-5 2-pyrrolidinon 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 56-12-2 4-amino-n-butyric acid 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 6937-16-2 ethyl γ-aminobutyrate hydrochloride 

Downstream Products

• 1374567-35-7 C₂₇H₂₈F₃N₅O₄ 
• 91596-61-1 1-(piperidin-4-yl)pyrrolidin-2-one 

Relevant academic research and scientific papers

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

Discovery of a tetrahydropyrimidin-2(1 H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor

Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c] imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.

BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

Biaryl-substituted tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions media

High-yielding syntheses of 1-piperidin-4-yl butyro- and valerolactams through a tandem reductive animation-lactamization (reductive lactamization)

We report a procedure for the concise and high-yielding syntheses of 1-piperidin-4-yl-substituted butyro- and valero-lactams. Beginning with 1-benzyl-4-piperidone and γ- or δ-amino esters or acids, we have effected a tandem reductive animation lactamizati

Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors

The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)- (methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors.